Home » Stocks » SNOA

Sonoma Pharmaceuticals, Inc. (SNOA)

Stock Price: $7.76 USD -0.12 (-1.51%)
Updated Jun 16, 2021 10:12 AM EDT - Market open
Market Cap 16.54M
Revenue (ttm) 21.05M
Net Income (ttm) -1.66M
Shares Out 2.05M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $7.76
Previous Close $7.88
Change ($) -0.12
Change (%) -1.51%
Day's Open 7.82
Day's Range 7.70 - 7.82
Day's Volume 4,306
52-Week Range 6.00 - 15.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has entered into an agreement with EMC Pharma LLC for the exclusive right to manage, market, and distribute Sonoma's HOCl-based prescription dermatology and eye...

2 months ago - Benzinga

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, In...

3 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ:...

3 months ago - Business Wire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - February 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonom...

3 months ago - Newsfile Corp

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

3 months ago - Business Wire

NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceutica...

4 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - February 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of So...

4 months ago - Newsfile Corp

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, ...

4 months ago - PRNewsWire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

4 months ago - Business Wire

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. ...

4 months ago - PRNewsWire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA...

5 months ago - Business Wire

NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA).   Such investors are ...

5 months ago - GlobeNewsWire

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, developing ...

Other stocks mentioned: DARE, MDNAF
5 months ago - Benzinga

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.

5 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such i...

5 months ago - Newsfile Corp

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA).   Such investors are ...

6 months ago - GlobeNewsWire

Sonoma Pharmaceuticals (SNOA) is in the news Friday after announcing a deal with Crown Laboratories that has SNOA stock on the rise. The post Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketi...

6 months ago - InvestorPlace

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 8, 2020) - Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Sonom...

6 months ago - Newsfile Corp

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA).   Such investors are ...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are ad...

6 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.

6 months ago - Business Wire

NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such investors are advise...

6 months ago - PRNewsWire

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

6 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - November 25, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of S...

6 months ago - Newsfile Corp

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. ...

6 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pha...

6 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ:...

6 months ago - Business Wire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

6 months ago - Business Wire

The Covid-19 pandemic has given a significant boost to many industries such as manufacturers of gloves, masks, sanitizers, PPE (personal protective equipment), health insurance providers, and many more ...

Other stocks mentioned: CLX, CMD, ECL, KMB, NEOG
8 months ago - GuruFocus

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.

8 months ago - Business Wire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.

9 months ago - Business Wire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.

10 months ago - Business Wire

Sonoma Pharmaceuticals (SNOA) is in the news Wednesday after an update concerning its Microsafe disinfectant sent SNOA stock soaring. The post Sonoma Pharmaceuticals News: Why SNOA Stock Is Skyrocketing...

10 months ago - InvestorPlace

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc.

10 months ago - Business Wire

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applica...

11 months ago - Business Wire

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday. The company announced that its Nanocyn Disinfectant & Sanitizer has received approval to be entered into the Australian registe...

1 year ago - Benzinga

Sonoma Pharmaceuticals (SNOA) is in the news Friday after approval for a disinfectant of the novel coronavirus sent SNOA stock skyrocketing. The post Sonoma Pharmaceuticals News: SNOA Stock Skyrockets 1...

1 year ago - InvestorPlace

Shares of Sonoma Pharmaceuticals Inc. SNOA, +216.63% nearly tripled on heavy volume in premarket trading Friday

1 year ago - Market Watch

PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, dif...

1 year ago - GlobeNewsWire

PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, dif...

1 year ago - GlobeNewsWire

PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public offering ...

1 year ago - GlobeNewsWire

PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of its ...

1 year ago - GlobeNewsWire

PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock.

1 year ago - GlobeNewsWire

Agreement with CEO and Interim CFO Bubba Sandford ends Amy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO

1 year ago - GlobeNewsWire

About SNOA

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the managemen... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 25, 2007
CEO
Amy Trombly
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
SNOA
Full Company Profile

Financial Performance

In 2019, SNOA's revenue was $18.94 million, a decrease of -0.18% compared to the previous year's $18.97 million. Losses were -$2.95 million, -75.03% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for SNOA is 9.00, which is an increase of 15.96% from the latest price.

Price Target
$9.00
(15.96% upside)